Bank of America’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-52,454
| Closed | -$210K | – | 8511 |
|
|
2025
Q2 | $210K | Sell |
52,454
-19,896
| -27% | -$49.3K | ﹤0.01% | 6165 |
|
|
2025
Q1 | $65.8K | Sell |
72,350
-32,003
| -31% | -$44.4K | ﹤0.01% | 6660 |
|
|
2024
Q4 | $289K | Sell |
104,353
-17,261
| -14% | -$65.7K | ﹤0.01% | 5910 |
|
|
2024
Q3 | $636K | Sell |
121,614
-18,408
| -13% | -$95.5K | ﹤0.01% | 5342 |
|
|
2024
Q2 | $624K | Buy |
140,022
+80,128
| +134% | +$389K | ﹤0.01% | 5199 |
|
|
2024
Q1 | $459K | Sell |
59,894
-13,804
| -19% | -$75.7K | ﹤0.01% | 5405 |
|
|
2023
Q4 | $314K | Sell |
73,698
-18,928
| -20% | -$67.2K | ﹤0.01% | 5810 |
|
|
2023
Q3 | $389K | Buy |
92,626
+37,123
| +67% | +$189K | ﹤0.01% | 5489 |
|
|
2023
Q2 | $309K | Buy |
55,503
+43,955
| +381% | +$260K | ﹤0.01% | 5565 |
|
|
2023
Q1 | $66.2K | Buy |
11,548
+4,443
| +63% | +$11.7K | ﹤0.01% | 6408 |
|
|
2022
Q4 | $7.46K | Buy |
7,105
+4,178
| +143% | +$7.3K | ﹤0.01% | 6975 |
|
|
2022
Q3 | $8K | Buy |
2,927
+2,920
| +41,714% | +$10.6K | ﹤0.01% | 7284 |
|
|
2022
Q2 | $0 | Sell |
7
-6,640
| -100% | -$28.9K | ﹤0.01% | 8180 |
|
|
2022
Q1 | $28K | Sell |
6,647
-5,206
| -44% | -$30.6K | ﹤0.01% | 7392 |
|
|
2021
Q4 | $81K | Buy |
11,853
+11,566
| +4,030% | +$99.9K | ﹤0.01% | 6985 |
|
|
2021
Q3 | $4K | Sell |
287
-2,217
| -89% | -$34.6K | ﹤0.01% | 7775 |
|
|
2021
Q2 | $43K | Sell |
2,504
-9,154
| -79% | -$159K | ﹤0.01% | 6901 |
|
|
2021
Q1 | $231K | Buy |
11,658
+11,479
| +6,413% | +$253K | ﹤0.01% | 5929 |
|
|
2020
Q4 | $4K | Sell |
179
-308
| -63% | -$7.34K | ﹤0.01% | 6855 |
|
|
2020
Q3 | $12K | Buy |
+487
| New | +$12.1K | ﹤0.01% | 6407 |
|
Bank of America's INZY Position: Q3 2025 in Review
Bank of America sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 52,454 shares — an estimated $210K sold.
Bank of America first reported a position in INZY in Q3 2020 and held it in 20 quarters. The position peaked at $636K in Q3 2024. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.
- Bank of America reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
- Bank of America sold 52,454 Inozyme Pharma shares in Q3 2025, an estimated $210K.
- Bank of America first reported a position in Inozyme Pharma in Q3 2020 and held it in 20 quarters.
- Bank of America's Inozyme Pharma position peaked at $636K in Q3 2024.
- 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.
Based on Bank of America's 13F filing for Q3 2025, filed 14 Nov 2025.